+Vote!
PR News Wire (Free subscription) | 01/10/2008
DUBLIN, Ireland, October 1 /PRNewswire-FirstCall/ -- Shire Limited
(LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,
announces that following the approval by shareholders at the Annual General
Meeting on September 24, 2008, the Company has changed its name to Shire
plc with effect from today.
Shire plc's ticker symbols on the London Stock Exchange and NASDAQ and
the ISIN...
+Vote!
Thinking made Easy (Free subscription) | 08/07/2008
Dear Vic Fabe I have another work for your writers to write for me. I have attached the description where all of the details of the coursework explained. The company of my choice is Shire PLC pharmaceutical company. The report of this company should include topics that we have covered...
+Vote!
Eurekalert (Free subscription) | 17/06/2008
( Shire plc ) Shire Ltd., the global specialty biopharmaceutical company, today announced the publication of data from a randomized, long-term safety and tolerability study of ulcerative colitis drug Lialda.
+Vote!
Medical News Today (Free subscription) | 21/05/2008
A post hoc analysis showing time to symptom resolution data from a study (study 302) of Shire plc's (LSE: SHP, NASDAQ: SHPGY) ulcerative colitis (UC) drug, LIALDATM, will be presented today at Digestive Disease Week (DDW). Study 302 (further referred to as "Kamm study," led by Dr Michael A.
+Vote!
Life Science World (Free subscription) | 20/05/2008
[NEWS] SAN DIEGO, May 20 /PRNewswire-FirstCall/ — A post hoc analysis showing time to symptom resolution data from a study (study 302) of Shire plc's (LSE: SHP, Nasdaq: SHPGY) ulcerative colitis (UC) drug, LIALDA™, will be presented today at Digestive Disease Week (DDW). Study 302 (further referred to as “Kamm study,” led by Dr Michael A. Kamm, from St Mark’s Hospital in London, UK), demonstrated LIALDA...
+Vote!
Red Orbit (Free subscription) | 12/05/2008
PHILADELPHIA, May 12 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today announced the launch of a 13-city mobile screening initiative for adults with Attention Deficit Hyperactivity Disorder (ADHD), a psychiatric disorder that affects approximately 4.4 percent of the U.S.
+Vote!
The Earth Times Online Newspaper (Free subscription) | 09/05/2008
BASINGSTOKE, England and PHILADELPHIA, May 9 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, announces that ordinary shareholders approved the scheme of arrange...
1Vote!
Medical News Today (Free subscription) | 09/05/2008
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints. "Adults with ADHD often find it challenging to focus and organize during the day.
+Vote!
Life Science World (Free subscription) | 08/05/2008
[NEWS] VYVANSE demonstrated significant improvement in ADHD symptoms in adults WASHINGTON, May 8 /PRNewswire-FirstCall/ — Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all...
1Vote!
Medical News Today (Free subscription) | 08/05/2008
Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
+Vote!
Medical News Today (Free subscription) | 08/05/2008
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
+Vote!
Medical News Today (Free subscription) | 08/05/2008
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA™ (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
1Vote!
Medical News Today (Free subscription) | 08/05/2008
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA(TM) (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
+Vote!
Eurekalert (Free subscription) | 07/05/2008
Shire plc, the global specialty biopharmaceutical company,presented today at a major scientific meeting findings from analyses ofpivotal trial results of an investigational once-daily medication, INTUNIV (guanfacine extended release), a selective alpha-2A-agonist. The data demonstrated that INTUNIV showed significant efficacy in reducing Attention Deficit Hyperactivity Disorder symptoms for patients...
+Vote!
Medical News Today (Free subscription) | 02/05/2008
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association...
